Lucid Diagnostics (LUCD) Set to Announce Earnings on Wednesday

Lucid Diagnostics (NASDAQ:LUCD) is set to release its earnings data before the market opens on Wednesday, November 13th. Analysts expect Lucid Diagnostics to post earnings of ($0.18) per share for the quarter.

Lucid Diagnostics (NASDAQ:LUCD) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $0.98 million during the quarter. On average, analysts expect Lucid Diagnostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lucid Diagnostics Stock Performance

NASDAQ LUCD opened at $1.04 on Friday. The stock has a market capitalization of $56.15 million, a price-to-earnings ratio of -0.85 and a beta of 1.41. Lucid Diagnostics has a 52 week low of $0.63 and a 52 week high of $1.58. The stock’s 50 day moving average price is $0.85 and its two-hundred day moving average price is $0.84.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on LUCD shares. Canaccord Genuity Group upgraded shares of Lucid Diagnostics to a “strong-buy” rating in a research note on Tuesday, August 13th. Ascendiant Capital Markets dropped their price objective on Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating on the stock in a research note on Tuesday, September 10th. Canaccord Genuity Group reissued a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research note on Tuesday, August 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $2.50 price target on shares of Lucid Diagnostics in a research note on Tuesday, August 13th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $3.94.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.